2014•The Lancet OncologyOpen access

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

Ian Judson, Jaap Verweij, Hans Gelderblom, Jörg T. Hartmann, Patrick Schöffski, Jean‐Yves Blay, J. Martijn Kerst, Josef Sufliarsky, Jeremy Whelan, Peter Hohenberger, Anders Krarup‐Hansen, Thierry Alcindor, Sandrine Marréaud, Saskia Litière, C. Hermans, Cyril Fisher, Pancras C.W. Hogendoorn, Angelo Paolo Dei Tos, Winette T.A. van der Graaf

Open full text 1,190 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

Open-access reader

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 1190 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Ifosfamide, Doxorubicin, Soft tissue sarcoma, Medicine, Sarcoma, Oncology, Soft tissue, Chemotherapy